

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (original). A method for identifying compounds that modulate binding of CK β 8-1 to FPRL-1 receptor, said method comprising:

providing cells expressing FPRL-1 receptor or functional fragment or variant thereof;

contacting said cells with CK β 8-1 or a functional fragment or variant thereof, in the presence or absence of a compound; and

measuring a signal indicative of receptor activation;

where an alteration to said signal in the presence of a compound identifies said compound as a compound that modulates binding of CK β 8-1 to FPRL-1 receptor.

Claim 2 (original). The method of claim 1, wherein the FPRL-1 receptor is expressed from a heterologous FPRL-1 receptor gene.

Claim 3 (original). The method of claim 1, wherein the FPRL-1 receptor is mammalian.

Claim 4 (original). The method of claim 3, wherein the FPRL-1 receptor is human.

Claim 5 (original). The method of claim 1, wherein said cells are mammalian cells.

Claim 6 (original). The method of claim 5, wherein the cells are human cells.

Claim 7 (original). The method of claim 1, wherein said measuring is performed using a FLIPR assay.

Claim 8 (original). The method of claim 1, wherein the signal measured is modulation of intracellular phospholipase C activity, intracellular adenylyl cyclase activity or intracellular calcium concentration.

Claim 9 (original). The method of claim 1, wherein the CK β 8-1 is CK β 8-1 (aa46-137).

Claim 10 – 33 (canceled)